ADTX Latest Press Releases

-- June 9, 2026 --

Aditxt Signed Definitive Agreement Valuing Ignite Proteomics at Approximately $150 Million Business Wire 7:45 AM

-- June 8, 2026 --

Ignite Proteomics Announces Prospective 10,000-Patient Oncology Registry to Evaluate Functional Proteomics in Cancer Therapy Selection Business Wire 8:15 AM

-- June 1, 2026 --

Aditxt, Inc. Appoints Jeffrey M. Busch as Interim Chief Executive Officer; Founder and Former CEO of $1B NYSE Enterprise Which Delivered ~8.5% Dividends to Shareholders Business Wire 8:15 AM

-- May 14, 2026 --

Aditxt, Inc. (NASDAQ: ADTX) Announces 1-for-27 Reverse Stock Split Effective at the Open of Trading on May 18, 2026 Business Wire 8:15 AM

-- April 20, 2026 --

Dana-Farber Cancer Institute Study Demonstrates Predictive Value of Ignite Proteomics' RPPA Platform for T-DXd (Enhertu) Therapy in Metastatic Breast Cancer Patients Business Wire 8:15 AM

-- March 19, 2026 --

Aditxt Subsidiary Ignite Proteomics Appoints Public Company Veteran Jeff Busch as Chief Executive Officer Business Wire 8:15 AM

-- March 13, 2026 --

Aditxt Acquires Ignite Proteomics to Address a Critical Challenge in Cancer Care: Optimizing Therapy Selection Business Wire 8:15 AM

-- March 5, 2026 --

Aditxt, Inc. (NASDAQ: ADTX) Announces 1-for-8 Reverse Stock Split Effective at the Open of Trading on March 9, 2026 Business Wire 8:30 AM

Market Data Delayed 15 Minutes

Questions? Feedback?Olark live chat software